Skip to main content
. Author manuscript; available in PMC: 2009 Oct 1.
Published in final edited form as: J Cereb Blood Flow Metab. 2009 Jan 14;29(4):853–860. doi: 10.1038/jcbfm.2008.162

Figure 2.

Figure 2

Comparison of ferumoxytol and gadodiamide enhancement in the rat U87 glioma xenographed model. (A) T1-weighted coronal MR of the rat brain before contrast. (B) At 60 secs after administration of ferumoxytol (6 mg/kg), no enhancement is visible. (C) At 60 secs postinjection of gadodiamide (0.05 mmol/kg, intravenously), the tumor shows increased signal. The small-molecular-weight agent can leak rapidly into the U87 tumor parenchyma causing contrast enhancement, but ferumoxytol, at early time points, is effectively a blood pool agent.